The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The study met its primary endpoint with flying colors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
